He shares his take on topics such as how the Baby KJ news is allowing investors and companies to think about scaling bespoke therapies, how AI might start to impact the clinical trial side of our business, and why he sees pharma adoption of AI as being important.

Greg Yap describes how his firm evaluates AI companies and lists other technology transformations to watch in the sector.